MYRIAD GENETICS INC's ticker is MYGN and the CUSIP is 62855J104. A total of 230 filers reported holding MYRIAD GENETICS INC in Q4 2019. The put-call ratio across all filers is 1.49 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2019 | $1,382,000 | +0.4% | 50,745 | +5.5% | 0.95% | -4.3% |
Q3 2019 | $1,377,000 | +8.0% | 48,113 | +4.8% | 1.00% | +12.5% |
Q2 2019 | $1,275,000 | -4.4% | 45,903 | +14.2% | 0.88% | -14.7% |
Q1 2019 | $1,334,000 | +13.5% | 40,185 | -0.6% | 1.04% | +0.4% |
Q4 2018 | $1,175,000 | -36.0% | 40,426 | +1.2% | 1.03% | -25.8% |
Q3 2018 | $1,836,000 | +4.9% | 39,929 | -14.8% | 1.39% | +9.4% |
Q2 2018 | $1,751,000 | +26.1% | 46,856 | -0.3% | 1.27% | +17.8% |
Q1 2018 | $1,389,000 | -53.8% | 46,989 | -46.3% | 1.08% | -11.0% |
Q4 2017 | $3,008,000 | +116.9% | 87,554 | +93.1% | 1.21% | -16.0% |
Q2 2016 | $1,387,000 | +1.2% | 45,341 | +23.8% | 1.45% | -0.3% |
Q1 2016 | $1,371,000 | -7.7% | 36,619 | +5.3% | 1.45% | -13.2% |
Q4 2015 | $1,486,000 | +11.1% | 34,783 | -3.3% | 1.67% | +12.4% |
Q3 2015 | $1,338,000 | +13.8% | 35,952 | +4.0% | 1.49% | +21.8% |
Q2 2015 | $1,176,000 | -51.9% | 34,569 | -51.7% | 1.22% | +4.8% |
Q1 2015 | $2,444,000 | +96.1% | 71,510 | +95.5% | 1.17% | -0.3% |
Q4 2014 | $1,246,000 | – | 36,580 | – | 1.17% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Camber Capital Management LP | 5,000,000 | $90,850,000 | 3.94% |
Altium Capital Management LP | 221,000 | $4,016,000 | 1.61% |
DISCIPLINED GROWTH INVESTORS INC /MN | 1,900,787 | $34,537,000 | 0.93% |
Zebra Capital Management LLC | 15,352 | $279,000 | 0.82% |
PFM Health Sciences, LP | 1,177,250 | $21,391,000 | 0.82% |
EARNEST PARTNERS LLC | 6,462,138 | $117,417,000 | 0.78% |
Glenview Capital Management | 1,696,791 | $30,831,000 | 0.77% |
AIMZ Investment Advisors, LLC | 42,085 | $765,000 | 0.37% |
Phocas Financial Corp. | 127,949 | $2,325,000 | 0.35% |
Redhawk Wealth Advisors, Inc. | 34,680 | $630,000 | 0.29% |